Curadev recently received permission from the US FDA to commence FIH trials with systemically administered CRD3874 in patients with advanced/metastatic solid cancers
Curadev Pharma has created a Clinical Advisory Group (CAG) comprising eminent oncologists to guide the design and execution of immune-oncology clinical trials with CRD3874, its lead non-nucleoside, allosteric small molecule STING agonist. Curadev recently received permission from the US FDA to commence FIH trials with systemically administered CRD3874 in patients with advanced/metastatic solid cancers.
Dr Arjun Surya, CEO and CSO, Curadev said, “We are honoured to work with such an esteemed group of accomplished clinician-researchers. The expertise of these KOLs in the early stages of clinical development will be instrumental in unlocking the promise of CRD3874.”
The advisors are Dr Navin Khattry, Deputy Director, Clinical Research Center, ACTREC, Mumbai, Dr Eileen Parkes, Group Leader, Innate Tumor Immunology, University of Oxford, UK; Dr Jacob Sands, Thoracic Oncology, Dana Farber Cancer Institute, Harvard University, USA; Dr K Govind Babu, Medical Oncologist, St Johns Medical College and Hospital, Bengaluru.
